Product image of Ivabradina Alter (Ivabradine Hydrochloride) supplied by GNH India

Ivabradina Alter

Active Ingredient:
Ivabradine Hydrochloride
Origin:
EU

Ivabradina Alter (Ivabradine Hydrochloride)

Ivabradine, the active ingredient in Ivabradina Alter, is a If channel inhibitor presented as an oral tablet for oral use. It reduces heart rate in patients with chronic stable angina and in those with heart failure with reduced ejection fraction, improving symptoms and exercise capacity.

GNH India supplies Ivabradina Alter as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product complies with EU quality standards and is available for bulk distribution to healthcare providers across multiple regions.

Manufacturer / TM Owner

Alter S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Ivabradina Alter acts on the cardiac If channel to lower heart rate in several cardiovascular conditions.

  • Chronic stable angina: reduces frequency of angina attacks and improves exercise tolerance.
  • Heart failure with reduced ejection fraction: lowers resting heart rate, alleviates symptoms and may decrease hospitalization risk.
  • Patients intolerant to beta‑blockers: provides heart‑rate reduction without beta‑adrenergic blockade, offering an alternative therapeutic option.

How It Works

  • Ivabradine selectively blocks the funny (If) current in the sinoatrial node by binding to the channel pore, which slows the spontaneous depolarization of pacemaker cells. This action reduces the slope of phase 4 depolarization, leading to a dose‑dependent decrease in heart rate while preserving myocardial contractility and blood pressure. The drug does not affect ventricular repolarization or systemic vascular resistance, allowing a focused chronotropic effect.

Side Effects

Ivabradina Alter may be associated with several adverse reactions, which are categorized by frequency and severity.

Common Side Effects

  • Bradycardia: resting heart rate may fall below 60 bpm.
  • Visual disturbances (phosphenes): transient luminous phenomena.
  • Headache: mild to moderate intensity.
  • Dizziness: sensation of light‑headedness, especially on standing.

Serious or Rare Side Effects

  • Symptomatic bradycardia: may cause fatigue, syncope or hypotension.
  • Atrial fibrillation: new‑onset irregular rhythm.
  • Severe hypotension: marked drop in blood pressure requiring medical attention.
  • Allergic reactions: rash, pruritus or anaphylaxis in rare cases.

Precautions & Warnings

Before prescribing Ivabradina Alter, clinicians should consider several precautionary measures to ensure patient safety.

  • Heart rate monitoring: avoid use in patients with resting heart rate below 60 bpm.
  • Conduction disorders: caution in individuals with sick sinus syndrome or second‑degree AV block.
  • Hepatic impairment: dose adjustment may be required in severe liver disease.
  • Concomitant bradycardic agents: monitor closely when combined with beta‑blockers, calcium‑channel blockers or digoxin.
  • CYP3A4 inhibitors: avoid strong inhibitors; moderate inhibitors require dose reduction.
  • Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture.

Avoid Interactions

Ivabradina Alter can interact with other medicines, influencing its plasma concentration or additive cardiac effects.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may markedly increase ivabradine exposure.
  • Co‑administration with other heart‑rate‑lowering drugs (beta‑blockers, diltiazem, verapamil): risk of excessive bradycardia.

Moderate Interactions (Monitor Closely)

  • Moderate CYP3A4 inhibitors (e.g., erythromycin, fluconazole): may raise ivabradine levels modestly.
  • Drugs affecting cardiac conduction (e.g., digoxin, amiodarone): may enhance bradyarrhythmic risk.
  • QT‑prolonging agents: combined use may increase arrhythmia potential.

Frequently Asked Questions

Ivabradina Alter contains ivabradine, which is prescribed to lower heart rate in patients with chronic stable angina and in those with heart failure with reduced ejection fraction. By reducing the heart rate, it helps relieve angina symptoms and can improve functional capacity in heart‑failure patients.

Ivabradine works by selectively inhibiting the funny (If) current in the sinoatrial node. This slows the spontaneous depolarisation of pacemaker cells, producing a dose‑dependent reduction in heart rate while leaving myocardial contractility and blood pressure largely unchanged.

The exact dose of ivabradine is determined by the prescribing clinician based on the individual’s clinical condition, heart‑rate response and tolerability. Typical regimens start with a low dose that may be titrated, but the specific amount and schedule should follow the prescriber’s order.

Safety data for ivabradine in pregnancy and lactation are limited. The product should be used only if the potential benefit justifies any possible risk to the fetus or infant, and it is generally avoided unless specifically recommended by a qualified healthcare professional.

To request Ivabradina Alter, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both ivabradine and beta‑blockers lower heart rate, but ivabradine does so by blocking the If current without affecting beta‑adrenergic receptors. This makes it useful for patients who cannot tolerate beta‑blockers or need additional heart‑rate reduction beyond what beta‑blockers provide.

Store Ivabradina Alter at ambient temperature, preferably below 25 °C. Keep the tablets in the original container, protect them from moisture and direct sunlight, and ensure the packaging remains sealed until use.

Ivabradina Alter is taken orally, usually as a tablet. It can be swallowed with or without food, according to the prescriber’s instructions. Patients should follow the dosing schedule provided by their healthcare professional.

Serious adverse events include symptomatic bradycardia, atrial fibrillation, severe hypotension and rare allergic reactions such as anaphylaxis. Patients should be monitored for these signs, especially when combined with other heart‑rate‑lowering agents.

Ivabradina Alter is contraindicated in patients with a resting heart rate below 60 bpm, those with sick sinus syndrome, second‑degree or higher atrioventricular block (unless a pacemaker is present), and individuals taking strong CYP3A4 inhibitors. It should also be avoided in patients with known hypersensitivity to ivabradine.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Ivabradine Hydrochloride

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT